Tore Saxne mainly focuses on Rheumatoid arthritis, Internal medicine, Arthritis, Immunology and Infliximab. His work deals with themes such as Prednisolone, Prospective cohort study, Immunopathology, Pathology and Cartilage, which intersect with Rheumatoid arthritis. His study in Internal medicine is interdisciplinary in nature, drawing from both Cartilage oligomeric matrix protein and Surgery.
The various areas that he examines in his Arthritis study include Concomitant, Progressive disease, Adverse effect and Severity of illness. As part of one scientific family, Tore Saxne deals mainly with the area of Immunology, narrowing it down to issues related to the Oncology, and often Antirheumatic Agents, Breast cancer, Colorectal cancer, Skin cancer and Cancer. His Infliximab research is multidisciplinary, incorporating elements of Pharmacotherapy, Antibody and Etanercept.
The scientist’s investigation covers issues in Rheumatoid arthritis, Internal medicine, Immunology, Arthritis and Pathology. His biological study spans a wide range of topics, including Reactive arthritis, Autoimmune disease, Connective tissue disease, Infliximab and Cohort. In his study, Observational study is inextricably linked to Physical therapy, which falls within the broad field of Internal medicine.
His Immunology research is multidisciplinary, incorporating perspectives in Prednisolone and Disease. His Arthritis research incorporates themes from Tumor necrosis factor alpha and Concomitant. Tore Saxne focuses mostly in the field of Pathology, narrowing it down to matters related to Cartilage and, in some cases, Cartilage oligomeric matrix protein, Osteoarthritis, Inflammation and Matrix.
His primary areas of study are Rheumatoid arthritis, Internal medicine, Immunology, Arthritis and Rheumatology. The concepts of his Rheumatoid arthritis study are interwoven with issues in Methotrexate, Cartilage oligomeric matrix protein, Antibody, Single-nucleotide polymorphism and Cohort. His Internal medicine study combines topics in areas such as Gastroenterology, Physical therapy and Surgery.
His Immunology study combines topics from a wide range of disciplines, such as Synovial fluid and Pneumococcal conjugate vaccine. The study incorporates disciplines such as Concomitant, Sustained remission, Tocilizumab and Abatacept in addition to Arthritis. His Rheumatology study also includes
Tore Saxne mostly deals with Rheumatoid arthritis, Internal medicine, Immunology, Rheumatology and Arthritis. His work in Rheumatoid arthritis tackles topics such as Cohort which are related to areas like Cause of death, Mortality rate, Confidence interval and Proportional hazards model. His Internal medicine study integrates concerns from other disciplines, such as Physical therapy and Weight-bearing, Surgery, Knee Joint.
His Immunology research is multidisciplinary, incorporating elements of Biomarker and Disease. His Rheumatology research integrates issues from Gastroenterology, Sports medicine, Cartilage oligomeric matrix protein, Pneumococcal conjugate vaccine and Conjugate vaccine. His work carried out in the field of Arthritis brings together such families of science as Young adult, Tocilizumab, Vaccination, Severity of illness and Abatacept.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.
Tore Saxne;Michael Palladino;Dick Heinegård;Norman Talal.
Arthritis & Rheumatism (1988)
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis
Lennart T H Jacobsson;Carl Turesson;Anders Gülfe;Meliha C Kapetanovic.
The Journal of Rheumatology (2005)
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
J Askling;C M Fored;Eva Baecklund;L Brandt.
Annals of the Rheumatic Diseases (2005)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Klaus Bendtzen;Pierre Geborek;Morten Svenson;Lotta Larsson.
Arthritis & Rheumatism (2006)
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Johan Askling;C. Michael Fored;Lena Brandt;Eva Baecklund.
Arthritis & Rheumatism (2005)
IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.
L.A.B. Joosten;M.M.A. Helsen;T. Saxne;F.A.J. van de Loo.
Journal of Immunology (1999)
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
J Askling;CM Fored;L Brandt;E Baecklund.
Annals of the Rheumatic Diseases (2005)
CARTILAGE OLIGOMERIC MATRIX PROTEIN: A NOVEL MARKER OF CARTILAGE TURNOVER DETECTABLE IN SYNOVIAL FLUID AND BLOOD
Tore Saxne;Dick Heinegård.
Rheumatology (1992)
Prognostic laboratory markers of joint damage in rheumatoid arthritis
Elisabet Lindqvist;Kerstin Eberhardt;Klaus Bendtzen;Dick Heinegard.
Annals of the Rheumatic Diseases (2005)
The role of the cartilage matrix in osteoarthritis
Dick Heinegård;Tore Saxne.
Nature Reviews Rheumatology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Lund University
Lund University
Karolinska Institute
Umeå University
Karolinska Institute
Lund University
Lund University
Leiden University Medical Center
Lund University
University Medical Center Groningen
Google (United States)
University of South Carolina
University of Toronto
European Bioinformatics Institute
University at Buffalo, State University of New York
University College London
The University of Texas Health Science Center at Houston
Charles University
Advanced Cell Technology (United States)
Princeton University
University of Groningen
University of Waterloo
University College of Osteopathy
Washington University in St. Louis
Stanford University